Loading...
Market
What will be the outcome of GRO Biosciences' lead NSAA-based therapy preclinical trials by end of 2024?
2
GRO Biosciences•Atlas Venture•Access Biotechnology•Leaps by Bayer•Redmile Group•Digitalis Ventures•iEndeavors•Pillar•Dan
Resolution / Starting Odds
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
Scientific publications, press releases from GRO Biosciences
Story
GRO Biosciences Secures $60.3M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Jul 19, 2024, 12:05 PM
GRO Biosciences has successfully closed a $60.3 million Series B financing round, co-led by Atlas Venture and Access Biotechnology. The funds will be used to advance its pipeline, which focuses on incorporating non-standard amino acid (NSAA) chemistries into therapies. This round also saw participation from previous investors, including Leaps by Bayer, Redmile Group, Digitalis Ventures, and iEndeavors. The financing marks a significant milestone for the company, which has been backed by Pillar since its pre-seed stage. Dan and his team have been pivotal in developing the GRO platform and product pipeline.
View original story
Similar markets
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Approved • 25%
Rejected • 25%
Request for more data • 25%
Other • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Yes • 50%
No • 50%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive • 25%
Negative • 25%
Inconclusive • 25%
No major trial outcome • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%